Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of loratadine plus rapamycin for lymphangioleiomyomatosis
2020-000702-29Phase 2Active
- Sponsor
- Bellvitge Institute for Biomedical Research
- Start
- Feb 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of loratadine in lymphangioleiomyomatosis (LAM), sponsored by Bellvitge Institute for Biomedical Research. Primary endpoint: Safety: incidence of adverse effects with loratadine plus rapamycin. Started Feb 2021; status: active.
02
Drugs
loratadine
03
Conditions
lymphangioleiomyomatosis (LAM)
Beyond the preview
Go deeper on 2020-000702-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000702-29.